P/E ratio for Repligen (RGEN)

P/E ratio history for Repligen from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Novavax NVAX	-1.75	-102.57%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	90.6	32.82%	🇺🇸 USA
Neurocrine Biosciences NBIX	60.5	-11.28%	🇺🇸 USA
General Electric GE	21.9	-67.90%	🇺🇸 USA
Thermo Fisher Scientific TMO	40.1	-41.22%	🇺🇸 USA
Bristol-Myers Squibb BMY	12.4	-81.81%	🇺🇸 USA
Pfizer PFE	15.8	-76.81%	🇺🇸 USA
Bio-Techne TECH	49.7	-27.17%	🇺🇸 USA
Sangamo Therapeutics SGMO	-0.6052	-100.89%	🇺🇸 USA
Charles River Laboratories CRL	21.5	-68.42%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.